Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. Alonso-Espinaco V, et al. Among authors: gallego r. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019. Epub 2014 May 12. Eur J Cancer. 2014. PMID: 24833563
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
Hörndler C, Gallego R, García-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernández-Martos C, Calatrava A, Marín-Aguilera M, Muñoz J, Castellví-Bel S, Castells A, Rubini M, Gascón P, Maurel J. Hörndler C, et al. Among authors: gallego r. Cancer Biol Ther. 2011 Jan 15;11(2):177-83. doi: 10.4161/cbt.11.2.13839. Epub 2011 Jan 15. Cancer Biol Ther. 2011. PMID: 21099348
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Gascón P, Castellví-Bel S, Maurel J. Garcia-Albeniz X, et al. Among authors: gallego r. Tumour Biol. 2011 Apr;32(2):417-24. doi: 10.1007/s13277-010-0136-3. Epub 2010 Nov 23. Tumour Biol. 2011. PMID: 21104178
Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.
Martínez-Fernandez A, García-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Augé JM, Longarón R, Gascón P, Lacy A, Castells A, Maurel J. Martínez-Fernandez A, et al. Among authors: gallego r. Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9. Epub 2009 Mar 4. Ann Surg Oncol. 2009. PMID: 19259740 Clinical Trial.
Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD).
Carrera G, Garcia-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pagés M, Torres F, Maurel J. Carrera G, et al. Among authors: gallego r. Rev Recent Clin Trials. 2011 May;6(2):158-70. doi: 10.2174/157488711795177868. Rev Recent Clin Trials. 2011. PMID: 21241233 Review.
312 results